⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 13, 2024Expert Opinion on Drug Safety

Differences in ocular adverse events associated with phosphodiesterase-5 inhibitors: a real-world pharmacovigilance study

Guixiang Chen Li Zhang Siting Zhao Hao Huang Zhiwen Fu

View at Publisher

Ask AI

Bookmark

Share

Abstract

Our study aims to characterize the ocular safety profiles of phosphodiesterase type 5 (PDE5) inhibitors and explore the differences among different PDE5 inhibitors.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chen et al. (2024) studied this question.

synapsesocial.com/papers/68e6a612b6db643587628d2b https://doi.org/10.1080/14740338.2024.2355335

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Major adverse cardiovascular events related to phosphodiesterase 5 inhibitors: analysis of real-life data from Eudra-Vigilance database2024 · 7 citations
2Head-to-head Comparison of the Safety and Efficacy Profiles of Three Phosphodiesterase Type 5 Inhibitors through Patient-reported Outcomes of 130 000 Patients from a Direct-to-consumer Platform Database2025
3Phosphodiesterase Type-5 Inhibitors and GlaucomaCase Report · 2026
4Associations between phosphodiesterase type 5 inhibitors and vascular function: a systematic review and meta-analysis on randomized-controlled trialsmeta-analysis · 2025 · 2 citations
5Phosphodiesterase 5 inhibitor use and incident diabetic retinopathy in men with erectile dysfunction and type 2 diabetes: a propensity-matched cohort studyCohort Study · 2026

More related papers

Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors2011
The safety and efficacy of phosphodiesterase type 5 inhibitors in the treatment of diabetic erectile dysfunction: a systematic review and meta-analysis2025
Safety of Phosphodiesterase-5 Inhibitors in Valvular Heart Disease2021

More from Expert Opinion on Drug Safety

Long-term safety of treatment of hemophilia A: a comprehensive reviewTue,
Tolerance of methotrexate co-administered with pegloticase in patients with uncontrolled gout: overview of the findings from the mirror RCTWed,